MedTrace Logo

Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin

NCT03584360 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-04-18

No results posted yet for this study

Summary

Changes in microbiome have been reported recently in psoriasis lesions compared to healthy surround skin. Preliminary data showed that systemic treatments of psoriasis induce modification of the skin microbiome that becomes similar to healthy individuals after successful treatment. The causative role of microbiome in psoriasis remains in debate. The modification of skin microbiome is suspected to be able to activate the innate immune response, namely natural killers (NKs) and immune lymphoid cells (ILCs). Three types of ILCs have been reported. ILC1 (immune lymphoid cells1) that trigger a Th1 response, ILC2 (immune lymphoid cells 2) that stimulate Th2 response and ILC3 (immune lymphoid cells 3) that induce Th17 response. Interestingly, ILC2 have been reported to be increased in atopic dermatitis while ILC3 are increased in psoriasis.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

Betamethasone-Calcipotriene Topical

Comparison between betamethasone-calcipotriol and placebo

DRUG

Betamethasone-Calcipotriene Topical

Comparison between betamethasone-calcipotriol and betamethasone

DRUG

Betamethasone-Calcipotriene Topical

Comparison between betamethasone-calcipotriol and propionate de clobetasol

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nice

    lead OTHER

Principal Investigators

  • Thierry PASSERON, MD, PhD · university hospital center of nice

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-24
Primary Completion
2018-09-24
Completion
2019-03-07

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03584360 on ClinicalTrials.gov